Advanced Therapeutics in Rheumatoid Arthritis (RA)

Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study ID
NCT03976245
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).

Key Dates

Start date
Mar 1, 2020
Status verified
Nov 2024
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025

Study Design

Enrollment
144 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: etanercept
    etanercept 50 mg subcutaneously injected per week
  • Active Comparator: tofacitinib
    tofacitinib 5 mg orally daily

Primary Outcome Measure

Retention Rates [ Time Frame: 24 months ]

Central Contacts

Related Studies